金吾财讯 | 诺瓦瓦克斯医药(NVAX)股价疲软，截止发稿，跌21.87%，报9.845美元。美FDA已对其新冠病毒和流感疫苗临床试验采取了临床暂停，此举是由于中期试验中一名参与者出现了运动神经病例。公司首席医疗官罗伯特·沃克在声明中表示，“我们正在与FDA密切合作，提供必要信息，以帮助他们更好地理解这一观察结果并解决临床暂停问题。”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.